Volume 108, Issue 2, Pages 284–288
Caroline Juneau, M.D., Emily Kraus, M.D., Marie Werner, M.D., H.C.L.D., Jason Franasiak, M.D., T.S., Scott Morin, M.D., George Patounakis, M.D., Ph.D., Thomas Molinaro, M.D., M.S.C.E., Dominique de Ziegler, M.D., Richard T. Scott, M.D., H.C.L.D.
To determine whether endometriosis ultimately results in an increased risk of embryonic aneuploidy.
Patients participating in an in vitro fertilization (IVF) cycle from 2009–2015 using preimplantation genetic screening (PGS) who had endometriosis identified by surgical diagnosis or by ultrasound findings consistent with a persistent space-occupying disease whose sonographic appearance was consistent with endometriosis.
Main Outcome Measure(s)
Rate of aneuploidy in endometriosis patients undergoing IVF compared to controls without endometriosis undergoing IVF.
There were 305 patients with endometriosis who produced 1,880 blastocysts that met the criteria for inclusion in the endometriosis group. The mean age of the patients with endometriosis was 36.1 ± 3.9 years. When the aneuploidy rates in patients with endometriosis and aneuploidy rates in patients without endometriosis were stratified by Society for Assisted Reproductive Technology age groups and compared, there were no statistically significant differences in the rate of aneuploidy (odds ratio 0.85; 95% confidence interval, 0.84–0.85).
Patients with endometriosis undergoing IVF have aneuploidy rates equivalent to their age-matched peers in IVF population who do not have endometriosis.